---
schema_version: "secwatch.filing_event.v1"
accession: "0001606498-25-000106"
form_type: "8-K"
ticker: "AVNS"
cik: "0001606498"
company_name: "AVANOS MEDICAL, INC."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:44:01.424578+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Avanos Q2 net loss $76.8M, goodwill impairment $77M; HA divestiture completed July 31

## Summary
- Q2 net sales $175M (+1.9% YoY); net loss $76.8M vs $4.3M income a year ago.
- Adjusted EPS $0.17 vs $0.34; adjusted EBITDA $17.0M vs $26.8M YoY.
- Recorded $77M goodwill impairment in PM&R segment due to market cap pressure.
- Divested HA product line (TriVisc, GenVisc 850) to Channel-Markers Medical on July 31, 2025.
- Appointed Scott Galovan as CFO effective Aug 1, 2025; CEO Pacitti appointed to Board.

## SEC filing metadata
- accession: 0001606498-25-000106
- form_type: 8-K
- ticker: AVNS
- cik: 0001606498
- company_name: AVANOS MEDICAL, INC.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1606498/000160649825000106/0001606498-25-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1606498/000160649825000106/avns-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001606498-25-000106
- JSON: https://secwatch.observer/filing/0001606498-25-000106.json
- Plain text: https://secwatch.observer/filing/0001606498-25-000106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.